Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis c genotype 2 or 3

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Alsiö, Åsa ^a   Rembeck, Karolina ^a   Askarieh, Galia ^a   Christensen, Peer Brehm ^b   Färkkilä, Martti ^c   Langeland, Nina ^d   Buhl, Mads ^e   Pedersen, Court ^b   Mørch, Kristine ^d   Haagmans, Bart L ^f   Nasic, Salmir ^g   Westin, Johan ^a   Hellstrand, Kristoffer ^a   Norkrans, Gunnar ^a   Lagging, Martin ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF HELSINKI   (Finland)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e AARHUS UNIVERSITY   (Denmark)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g SKARABORG HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; GENETICS; HEPATITIS C VIRUS; LIVER; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS C VIRUS;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; MALE; OBESITY; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84861378637     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037521     Document Type: Article

References (29)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, et al. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-362.
2. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, et al. (1989) Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321: 1494-1500.
3. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, et al. (1990) Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 87: 6547-6549.
4. Lagging LM, Westin J, Svensson E, Aires N, Dhillon AP, et al. (2002) Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver 22: 136-144.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, et al. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355.
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
8. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, et al. (2004) Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291: 2847-2850.
9. Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, et al. (2007) Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 14: 29-35.
10. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J, (2002) Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 97: 2408-2414.
11. Bressler BL, Guindi M, Tomlinson G, Heathcote J, (2003) High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38: 639-644.
12. Charlton MR, Pockros PJ, Harrison SA, (2006) Impact of obesity on treatment of chronic hepatitis C. Hepatology 43: 1177-1186.
13. Harrison SA, (2006) Correlation between insulin resistance and hepatitis C viral load. Hepatology 43: 1168; author reply 1168-1169.
14. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, et al. (2004) Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 12: 962-971.
15. Lam NP, Pitrak D, Speralakis R, Lau AH, Wiley TE, et al. (1997) Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci 42: 178-185.
16. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, et al. (2008) Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 47: 1837-1845.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
18. Qu HQ, Li Q, Rentfro AR, Fisher-Hoch SP, McCormick JB, (2011) The definition of insulin resistance using HOMA-IR for Americans of Mexican descent using machine learning. PloS one 6: e21041.
19. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699.
20. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R, (2002) Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 37: 837-842.
21. Pedersen C, Alsio A, Lagging M, Langeland N, Farkkila M, et al. (2011) Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection. J Viral Hepat 18: 245-251.
22. Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, et al. (2007) Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 46: 971-981.
23. Pattullo V, Ravindran NC, Mazzulli T, Wong DK, Heathcote EJ, (2010) Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C. J Viral Hepat 17: 834-838.
24. Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, et al. (2008) Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 48: 1033-1043.
25. Reddy KR, Shiffman ML, Rodriguez-Torres M, Cheinquer H, Abdurakhmanov D, et al. (2010) Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology 139: 1972-1983.
26. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, et al. (2009) Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361: 580-593.
27. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, et al. (2004) Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53: 413-419.
28. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, et al. (2002) Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 51: 89-94.
29. McLauchlan J, (2009) Lipid droplets and hepatitis C virus infection. Biochim Biophys Acta 1791: 552-559.